Microbiome plays a crucial role in a number of diseases

We believe the microbiome is the key to unlocking the understanding and treatment of many diseases. A large number of untapped medical needs already are or shall soon be revisited through the microbiome prism.

Academic research is booming

Main features of the Microbiome field

Our investment portfolio

Stellate’s work is focused on the gut-brain axis to develop therapies for neurological diseases. Its most advanced project, STL-101 is a potential first-in-class, disease-modifying therapy for Parkinson’s disease (PD) that acts through neuroprotection. STL-101 is a synthetic form of queuine, a micronutrient made by gut bacteria, enriched in the CNS and crosses the blood-brain barrier.

Clinical studies expected in 2022

Founded out of research at MetaGenoPolis, NovoBiome develops Live Biotherapeutic Products (LBPs) targeting hepato-biliary disorders, based on exciting findings around the commensal bacterium Adlercreutzia equolifaciens. It benefits from disruptive platform for ex vivo studies combining: 1. high throughput functional metagenomics 2. human intestinal organoids 3. super resolution fluorescent confocal microscopy 4. deep learning algorithm.

Currently in pre-clinical development

Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases. Coave Therapeutics’ next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.
eureKARE SA 
1A, Heienhaff 
L-1736 Senningerberg